Combination therapy for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that has spread or cannot be removed with surgery.
- Your cancer must be measurable on scans, meaning it can be tracked with imaging.
- You should be able to take care of yourself (ECOG performance status 0 or 1).
- Your organs (like liver, kidneys, and blood cells) must be working well enough.
- Any side effects from previous treatments must have mostly resolved, except for hair loss or some nerve issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
This trial tests a new drug called QLS5133 for people with advanced solid tumors (cancers that have spread). The drug may help shrink tumors or slow their growth. The study is in two phases to find the right dose and see how well it works.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.